PMID: 11926437Apr 3, 2002Paper

Therapeutic options for Gram-positive infections

The Journal of Hospital Infection
M J Rybak

Abstract

Gram-positive infections impose a major burden on patients and the healthcare systems globally. The need to treat these infections correctly in an empirical fashion is of paramount importance. Further complicating this changing aetiology is the emergence of resistant strains which are no longer predictably susceptible to standard first-line antimicrobials such as oxacillin or vancomycin. Thus new agents such as linezolid have been developed to assist with initial empirical prescribing in infections where Gram-positive pathogens may be present. The characteristics of linezolid, including spectrum of activity, pharmacodynamic profile, tolerablility and overall efficacy should strengthen confidence when considering initial antimicrobial therapy in patients in risk areas. Future agents also being developed to fight multi-resistant Gram-positive infections include oritavancin, daptomycin and the glycylcyclines; however, these are still in the development phase.

References

Jan 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J W ChowM J Zervos
Mar 18, 2000·Journal of Chemotherapy·M J Wood
Mar 16, 2000·Drugs·D I Diekema, R N Jones
Sep 15, 2000·The Medical Letter on Drugs and Therapeutics
Oct 6, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J E McGowan
Oct 6, 2000·The Journal of Antimicrobial Chemotherapy·F P Tally, M F DeBruin
Feb 15, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E RubinsteinUNKNOWN Linezolid Nosocomial Pneumonia Study Group
Apr 26, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D E LowR N Jones
Jun 26, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·UNKNOWN European Committee on Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Inf
Nov 23, 2001·Pharmacotherapy·D J Kuter, G S Tillotson

❮ Previous
Next ❯

Citations

Jan 27, 2011·PloS One·Irina SinakevitchBrian H Smith
Mar 3, 2004·The Annals of Pharmacotherapy·Jack Brown, Burgess B Freeman
Aug 19, 2005·Expert Review of Anti-infective Therapy·André Bryskier
Mar 16, 2007·Expert Opinion on Emerging Drugs·Emma J Bishop, Benjamin P Howden

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.